Status:
COMPLETED
Descriptive Cohort of French Patients Treated With Carbonetherapy Since October 2010 Outside PHRC-ETOILE
Lead Sponsor:
Hospices Civils de Lyon
Collaborating Sponsors:
Centre François Baclesse, Centre de lutte contre le cancer (CLCC)
Conditions:
Cancer
Cystic Carcinomas, Adenoid
Eligibility:
All Genders
18+ years
Brief Summary
Since the 1990s, carbonetherapy radiotherapy has been developed in a few sites around the world, mainly to treat inoperable and highly radioresistant tumors. In the absence of a treatment center of th...
Eligibility Criteria
Inclusion
- Inclusion Criteria :
- Patients aged ≥ 18 years at the time of inclusion
- Patients treated with Carbonetherapy outside PHRC-ETOILE from October 2010 to December 2023, after validation of their file by the health insurance expert, under an agreement providing for reimbursement for indications similar to those of PHRC-ETOILE for patients unable or unwilling to be included (re-irradiation, rare tumors or tumors of exceptional presentation not included in PHRC-ETOILE inclusion criteria). These include, by way of illustration :
- Unresectable or non-operable cancers, or those with macroscopically incomplete resection (R2)
- Radiation-resistant cancers considered eligible according to the following indicative list:
- Cystic adenoid carcinomas (CAK) of the head and neck (excluding laryngeal and tracheal localizations)
- Soft-tissue sarcomas
- Pleiomorphic rhabdomyosarcomas only
- Retroperitoneal sarcomas subject to technical feasibilitý - movement)
- Osteosarcomas of any location and any grade
- Chondrosarcomas (skull base excluded) grade greater than 2
- Chordomas of the axial skeleton and pelvis (excluding skull base)
- Angiosarcomas
- Patients who have not objected to the re-use of medical data for cancer research purposes, and who agree to be contacted by the investigator to complete the quality of life and care pathway questionnaires.
- Exclusion Criteria:
- Refusal by the living patient to participate in research
- Failure to carry out initially planned carbon therapy treatment
Exclusion
Key Trial Info
Start Date :
May 23 2025
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 14 2025
Estimated Enrollment :
62 Patients enrolled
Trial Details
Trial ID
NCT06535997
Start Date
May 23 2025
End Date
July 14 2025
Last Update
August 6 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre François Baclesse, Centre de lutte contre le cancer (CLCC)
Caen, France, 14076
2
Hôpital Michallon, CHU de Grenoble-Alpes
Grenoble, France, 38043